In a 2014 study, Long et al. identified 24 genes that are differentially expressed in PCas of dissimilar BCR risk, which can be utilized to enhance the prediction precision and thereby improve the clinical management of prostate cancer [1]. This evidence concerns the gene BCR and prostate carcinoma.